International Clinical Trial: Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07730528) titled 'Study to Evaluate the Safety and Efficacy of Humacyte's Coronary Tissue Engineered Vessel (CTEV) in Patients With Coronary Artery Disease Requiring Coronary Artery Bypass Grafting (CABG)' on July 23.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Humacyte, Inc.

Condition: Coronary Artery Disease

Intervention: Biological: Humacyte Coronary Tissue Engineered Vessel (CTEV)

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: September 2026

Target Sample Size: 1...